A Catalyst for Change: The European Cancer Patient's Bill of RightsMark Lawler, Patrick G. Johnston, PierFranco Conte et al.|The Oncologist|2014Cited by 46
Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumorsJean‐Charles Soria, Luca Gianni, C. Sessa et al.|Cancer Research|2008Cited by 8